|
|
|
|
| LEADER |
04926nam a2200601 4500 |
| 001 |
ocn923738621 |
| 003 |
OCoLC |
| 005 |
20180501122027.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
151012s2015 ne ob 001 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCQ
|d N$T
|d CDX
|d YDXCP
|d EBLCP
|d GrThAP
|
| 019 |
|
|
|a 925438620
|a 928483679
|a 931586127
|a 932328963
|
| 020 |
|
|
|a 9780128025222
|q electronic bk.
|
| 020 |
|
|
|a 0128025220
|q electronic bk.
|
| 020 |
|
|
|a 9780128022566
|
| 035 |
|
|
|a (OCoLC)923738621
|z (OCoLC)925438620
|z (OCoLC)928483679
|z (OCoLC)931586127
|z (OCoLC)932328963
|
| 050 |
|
4 |
|a RB40
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.0756
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Advances in clinical chemistry.
|n Volume 71 /
|c Gregory Makowski, editor.
|
| 264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c 2015.
|
| 300 |
|
|
|a 1 online resource (332 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Clinical Chemistry ;
|v v. 71
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 500 |
|
|
|a Title from title details screen (ScienceDirect, viewed October 12, 2015).
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Title page; Table of Contents; Copyright; Contributors; Preface; Chapter One: Biomarkers in Breast Cancer: Where Are We and Where Are We Going?; Abstract; 1 Use of Biomarkers in the Identification of Women at Increased Risk of Developing Breast Cancer (Risk Assessment); 2 Use of Biomarkers in Determining Prognosis; 3 Use of Biomarkers in Guiding Treatment; 4 Use of Biomarkers in the Postoperative Follow-Up of Asymptomatic Patients Following Curative Surgery; 5 Use of Biomarkers in Monitoring Therapy in Patients with Metastasis; 6 Emerging Biomarkers for Breast Cancer; 7 Conclusion
|
| 505 |
8 |
|
|a AcknowledgmentsChapter Two: Polycystic Ovary Syndrome-Epigenetic Mechanisms and Aberrant MicroRNA; Abstract; 1 Introduction; 2 The Epigenetic Landscape; 3 miRNA; 4 Conclusions; Acknowledgments; Chapter Three: EN2 in Prostate Cancer; Abstract; 1 Introduction; 2 Risk Factors and Conventional Biomarkers of Prostate Cancer; 3 Biomarkers with Clinical Application in Urine; 4 Antitumor Antibodies as Biomarkers; 5 The Homeobox Gene Superfamily; 6 The Biology of En; 7 En in Cancer; 8 En as a Potential Biomarker in Cancer; 9 EN2 in Prostate Cancer
|
| 505 |
8 |
|
|a 10 EN2 as a Diagnostic Marker and Marker of Significant Disease11 EN2 in Men at High Risk of Prostate Cancer; 12 Future Perspectives; 13 Conclusion; Chapter Four: Cytochrome P450 in Cancer Susceptibility and Treatment; Abstract; 1 Introduction; 2 Classification, Nomenclature, and Structure of Cytochromes P450; 3 Drug Metabolism; 4 Genetic Variations in CYP450 Isoforms; 5 CYP450 in Cancer Susceptibility; 6 CYP450 in Anticancer Therapy; 7 Conclusion; Acknowledgments; Chapter Five: The Importance of Accurately Assessing Renal Function in the Neonate and Infant; Abstract; 1 Introduction
|
| 505 |
8 |
|
|a 2 The Normal Development of Renal Function Before Birth3 Adaptation of Hemodynamics and Renal Function After Birth; 4 Can Nephrogenesis Continue After Preterm Birth?; 5 Measuring Renal Function; 6 Neonatal Kidney Size and Renal Function in Preterm Infants; 7 Should We Move to CysC-Derived eGFR When Dosing Aminoglycosides and Other Renally Excreted in Neonates?; Acknowledgments; Chapter Six: Systematic Assessment of the Hemolysis Index: Pros and Cons; Abstract; 1 Introduction; 2 The Hemolysis Index; 3 Pros and Cons; 4 Conclusions
|
| 505 |
8 |
|
|a Chapter Seven: Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and AtherosclerosisAbstract; 1 Introduction; 2 PPARα Expression; 3 PPARα Structure and Activation; 4 PPARα and Lipid Metabolism; 5 PPARα and Lipoprotein Metabolism; 6 The Roles of PPARα in Atherosclerosis; 7 Therapeutic Potential of PPARα Agonists in Atherosclerosis and Dyslipidemia; 8 Conclusions and Perspectives; Acknowledgments; Index
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
7 |
|a Clinical chemistry.
|2 fast
|0 (OCoLC)fst00864330
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Makowski, Gregory S.
|q (Gregory Stephen),
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Makowski, Gregory S.
|t Advances in Clinical Chemistry
|d : Elsevier Science,c2015
|
| 830 |
|
0 |
|a Advances in Clinical Chemistry ;
|v v. 71.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00652423/71
|z Full Text via HEAL-Link
|
